Rheumatoid arthritis is a painful, debilitating inflammatory disease that affects 24 million people worldwide. Despite advances in drug therapies, 40% of patients fail the first line of therapy and 20% fail the second line of therapy. These ‘drug-resistant’ patients remain affected by the disease and without hope of relief.

We are researching the development of a novel device that targets the abdominal vagus nerve to activate the body’s natural inflammatory reflex. Read about our research into treating drug-resistant rheumatoid arthritis.